Diosynth

Diosynth is a biopharmaceutical company that specializes in the development and manufacturing of active pharmaceutical ingredients (APIs) and biologics. The company has a long history of innovation and excellence in the field of biotechnology and pharmaceuticals.

History[edit | edit source]

Diosynth was originally founded as a division of Royal DSM, a global science-based company active in health, nutrition, and materials. Over the years, Diosynth has grown and evolved, becoming a leading player in the biopharmaceutical industry. In 2005, Diosynth merged with Organon International to form Schering-Plough's Organon BioSciences division. Later, in 2009, Schering-Plough was acquired by Merck & Co., and Diosynth became part of Merck's manufacturing network.

Services[edit | edit source]

Diosynth offers a wide range of services in the biopharmaceutical sector, including:

Development and manufacturing of active pharmaceutical ingredients (APIs)
Production of biologics, including monoclonal antibodies and recombinant proteins
Process development and optimization
Analytical and quality control services
Regulatory support and compliance

Facilities[edit | edit source]

Diosynth operates several state-of-the-art manufacturing facilities around the world. These facilities are equipped with advanced technologies and adhere to the highest standards of Good Manufacturing Practice (GMP). The company's main production sites are located in:

Research and Development[edit | edit source]

Diosynth is committed to innovation and invests heavily in research and development (R&D). The company collaborates with academic institutions, research organizations, and other industry partners to advance the field of biopharmaceuticals. Diosynth's R&D efforts focus on improving manufacturing processes, developing new biologics, and enhancing the quality and efficacy of existing products.